{"version":"1.0","type":"link","title":"Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.","author_name":"Dummer R 외","author_url":"https://prs-insight.online/author/Dummer%20R","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/167945","thumbnail_width":1200,"thumbnail_height":630}